Glenmark Pharmaceuticals has launched Phytonadione injectable emulsion through its US arm, targeting anticoagulant markets. The 10 mg/mL single-dose ampules are bioequivalent to Vitamin K1 Injectable Emulsion USP. This launch diversifies Glenmark's institutional product portfolio and reinforces their commitment to offering affordable alternatives, with the market valued at approximately USD 19.7 million annually. Glenmark Pharmaceuticals on Tuesday said its US arm has launched anticoagulant Phytonadione injectable emulsion. Glenmark Pharmaceuticals Inc., USA has launched Phytonadione injectable emulsion of strength 10 mg/mL single-dose ampules, the company said in a statement. The single-dose ampules is bioequivalent and therapeutically equivalent to the reference listed drug, Vitamin K1 Injectable Emulsion USP, 10 mg/mL of Hospira, Inc., it added.
Commenting on the launch, Glenmark President & Business Head, North America Marc Kikuchi said, it grows the company's ""portfolio of products within the institutional channel, while also strengthening our commitment to bring to market